Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III Study of Crovalimab Versus Eculizumab in Paroxysmal Nocturnal Hemoglobinuria
2019-004931-21Phase 3Active
- Sponsor
- Roche
- Start
- Jun 2020
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of crovalimab in paroxysmal nocturnal hemoglobinuria (PNH) (2 arms), sponsored by Roche. Primary endpoint: Transfusion avoidance. Started Jun 2020; status: active.
02
Drugs
crovalimab
03
Conditions
paroxysmal nocturnal hemoglobinuria (PNH)
Beyond the preview
Go deeper on 2019-004931-21.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-004931-21.